CYP19A1 and breast carcinoma: A recent Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis has now shown that aromatase inhibitors are also more effective than tamoxifen in premenopausal women with oestrogen receptor-positive (ER +) BC who received OFS [29].